A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin
- 13 July 1995
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 333 (2), 101-106
- https://doi.org/10.1056/nejm199507133330206
Abstract
Isotretinoin is effective in treating severe acne, but it is also teratogenic. To minimize pregnancies among exposed women, the manufacturer, together with the U.S. Food and Drug Administration, implemented a multicomponent Pregnancy Prevention Program in 1988. We report the results of an ongoing survey designed to assess compliance with this program.Keywords
This publication has 8 references indexed in Scilit:
- Methotrexate for Chronic Diseases in AdultsThe New England Journal of Medicine, 1995
- Methotrexate for the Treatment of Crohn's DiseaseThe New England Journal of Medicine, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum LeprosumThe Journal of Infectious Diseases, 1993
- Thalidomide inhibits the replication of human immunodeficiency virus type 1.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Epidemiology of isotretinoin exposure during pregnancyJournal of the American Academy of Dermatology, 1992
- When a Uniquely Effective Drug is TeratogenicThe New England Journal of Medicine, 1989
- Retinoic Acid EmbryopathyThe New England Journal of Medicine, 1985